EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma



Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma



Blood Coagulation & Fibrinolysis 5(6): 879-887



Clot-bound thrombin remains active and is less accessible to heparin-antithrombin III than fluid-phase thrombin. To determine whether clot-bound human thrombin is more susceptible to inactivation by direct thrombin inhibitors, the activity of a novel synthetic competitive thrombin inhibitor Ro 46-6240, recombinant hirudin and unfractionated heparin were compared with fluid-phase thrombin and clot-bound thrombin.

(PDF emailed within 0-6 h: $19.90)

Accession: 008877308

Download citation: RISBibTeXText

PMID: 7893925

DOI: 10.1097/00001721-199412000-00003



Related references

Inhibition of clot-bound and free by a novel synthetic thrombin inhibitor , recombinant hirudin and heparin in human plasma. Blood Coagulation & Fibrinolysis 5(6): 879-887, 1994

Inhibition of extrinsic and intrinsic thrombin generation by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coagulation & Fibrinolysis 6(6): 553-560, 1995

Inhibition of fluid phase and clot-bound thrombin by the thrombin exosite I ligand LU 58463: comparison with heparin and hirudin. Haematologica 87(10): 1116-1117, 2002

Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Thrombosis and Haemostasis 72(3): 381-386, 1994

Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. ADVENT Investigators. Thrombosis and Haemostasis 81(4): 498-501, 1999

Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 79(3): 657-665, 1989

Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin. Thrombosis and Haemostasis 88(2): 282-287, 2002

Effect of heparin, hirudin, and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats. Haemostasis 17(6): 321-328, 1987

Clot-bound thrombin activates platelets as potent as fluid-phase thrombin. Blood 88(10 SUPPL 1 PART 1-2): 48B, 1996

Inhibition of heparin-resistant microarterial thrombosis by recombinant hirudin: a specific thrombin inhibitor. Plastic and Reconstructive Surgery 95(5): 894-900, 1995

Comparison of thrombin-antithrombin complex (TAT) levels and fibrinopeptide A following thrombin incubation of human plasma using hirudin as an inhibitor of TAT formation. Thrombosis Research 61(3): 253-259, 1991

Determination of rDNA hirudin and a-human thrombin- hirudin complex in plasma samples: Enzyme linked immunosorbent assays for hirudin and complex vs. chromogenic thrombin substrate assay. Thrombosis Research 66(1): 33-42, 1992

Determination of r DNA hirudin and A-human thrombin- hirudin complex in plasma samples: enzyme linked immunosorbent assays for hirudin and complex vs. chromogenic thrombin substrate assay. Thrombosis Research 66(1): 33-42, 1992

Inhibition of thrombin-induced neuronal cell death by recombinant thrombomodulin and E5510, a synthetic thrombin receptor signaling inhibitor. Thrombosis and Haemostasis 82(3): 1071-1077, 1999

The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma. Thrombosis Research 113(1): 85-91, 2004